It's an ongoing protocol, not a one-time shot
Clinical studies have demonstrated increased dermal density and better overall skin remodeling
Novo Nordisk s executive vice president of Development, Martin Holst Lange, expressed confidence that larger trials could reveal weight loss of up to 25%, citing data from previous studies, including stand-alone trials of cagrilintide, to support this projection
Recent hypotheses suggest that GIP induces appetite suppression through independent receptors in the brain, mitigates gastrointestinal side effects of GLP-1 action, and prevents desensitization of GLP-1 receptors, thereby acting as a biased GLP-1RA [87]
We encourage you to discuss any decisions about treatment or care with your health care provider